Torisel Approved for Renal Cell Carcinoma Treatment

Thursday, May 31, 2007

Ijeoma Eleazu, PharmD

Torisel (Temsirolimus) was yesterday approved by the FDA for use in the treatment of renal cell carcinoma, a form of advanced kidney cancer.

Common adverse reactions associated with this drug include edema, loss of appetite, nausea, mouth sores, fatigue, and rash. The drug can also cause some abnormal lab test results, including high blood sugar, lipids and triglycerides, low red blood cell, white blood cell, and platelet counts, and elevated liver and kidney function tests.

Torisel is manufactured by Wyeth Pharmaceuticals and will be available in July 2007.

Photo courtesy of striatic

Labels: cancer, kidney, renal cell carcinoma, torisel

Permalink | Email Post

The Healthline Site, its content, such as text, graphics, images, search results, HealthMaps, Trust Marks, and other material contained on the Healthline Site ("Content"), its services, and any information or material posted on the Healthline Site by third parties are provided for informational purposes only. None of the foregoing is a substitute for professional medical advice, examination, diagnosis, or treatment. Always seek the advice of a physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on the Healthline Site. If you think you may have a medical emergency, call your doctor or 911 immediately. Please read the Terms of Service for more information regarding use of the Healthline Site.